Brokerages Set Hims & Hers Health, Inc. (NYSE:HIMS) PT at $45.27

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have received a consensus rating of “Reduce” from the fifteen brokerages that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $45.2727.

Several brokerages have issued reports on HIMS. BTIG Research reissued a “buy” rating and issued a $85.00 target price on shares of Hims & Hers Health in a research report on Tuesday, November 4th. Bank of America increased their price objective on shares of Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a research note on Tuesday, November 4th. KeyCorp assumed coverage on shares of Hims & Hers Health in a report on Tuesday, October 21st. They issued a “sector weight” rating on the stock. Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Truist Financial dropped their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a research note on Monday, August 18th.

Insider Buying and Selling

In other Hims & Hers Health news, insider Michael Chi sold 13,749 shares of the firm’s stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $694,324.50. Following the transaction, the insider directly owned 297,139 shares in the company, valued at $15,005,519.50. This trade represents a 4.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Oluyemi Okupe sold 145,000 shares of the firm’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $55.35, for a total transaction of $8,025,750.00. Following the transaction, the chief financial officer directly owned 128,984 shares in the company, valued at $7,139,264.40. This trade represents a 52.92% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 616,431 shares of company stock valued at $32,924,482. 13.71% of the stock is owned by company insiders.

Institutional Trading of Hims & Hers Health

A number of institutional investors have recently modified their holdings of the company. Ethic Inc. purchased a new position in shares of Hims & Hers Health during the 2nd quarter valued at about $348,000. Lake Hills Wealth Management LLC purchased a new position in shares of Hims & Hers Health in the second quarter valued at approximately $277,000. Intellectus Partners LLC purchased a new stake in shares of Hims & Hers Health during the second quarter worth $3,043,000. Occidental Asset Management LLC purchased a new stake in Hims & Hers Health during the 2nd quarter valued at about $305,000. Finally, Dakota Wealth Management acquired a new stake in shares of Hims & Hers Health in the second quarter valued at approximately $354,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Stock Up 2.0%

Shares of Hims & Hers Health stock opened at $37.05 on Monday. The company has a market cap of $8.43 billion, a price-to-earnings ratio of 68.61, a price-to-earnings-growth ratio of 7.18 and a beta of 2.41. The company’s 50 day moving average is $46.44 and its 200 day moving average is $50.05. Hims & Hers Health has a twelve month low of $23.97 and a twelve month high of $72.98. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The company had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The company’s revenue for the quarter was up 49.2% on a year-over-year basis. During the same period last year, the firm posted $0.32 EPS. Research analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current year.

Hims & Hers Health announced that its board has approved a stock repurchase program on Monday, November 17th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 3% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.